Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388613 | 0.86 | HTR2C (0.62) | HTR2CHTR2AHTR2B | |
| SCHEMBL15800579 | 0.86 | HTR2C (0.62) | HTR2CHTR2AHTR2B | |
| SCHEMBL5636371 | 0.86 | HTR2C (0.62) | HTR2CHTR2AHTR2B | |
| SCHEMBL5637064 | 0.85 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL5638490 | 0.85 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL5636468 | 0.85 | HTR2C (0.75) | HTR2CHTR2AHTR2B | |
| SCHEMBL5637201 | 0.85 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL5635151 | 0.84 | HTR2A (0.62) | HTR2CHTR2AHTR2B | |
| SCHEMBL5637170 | 0.84 | HTR2C (0.54) | HTR2CHTR2AHTR2B | |
| SCHEMBL5635413 | 0.81 | HTR2C (0.60) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.